UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/577,982	05/02/2006	Makoto Koizumi	06189/HG	2978
	7590 12/05/200 OLTZ, GOODMAN &	EXAMINER		
220 Fifth Avenue 16TH Floor NEW YORK, NY 10001-7708			STAPLES, MARK	
			ART UNIT	PAPER NUMBER
			1637	
			MAIL DATE	DELIVERY MODE
			12/05/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/577,982	KOIZUMI, MAKOTO	
Examiner	Art Unit	

Ma	ark Staples	1637
The MAILING DATE of this communication appears	on the cover sheet with the c	orrespondence address
THE REPLY FILED 14 November 2008 FAILS TO PLACE THIS AF	PPLICATION IN CONDITION FO	OR ALLOWANCE.
1. The reply was filed after a final rejection, but prior to or on the application, applicant must timely file one of the following repl application in condition for allowance; (2) a Notice of Appeal (for Continued Examination (RCE) in compliance with 37 CFR periods:	same day as filing a Notice of A ies: (1) an amendment, affidavit with appeal fee) in compliance v	Appeal. To avoid abandonment of this c, or other evidence, which places the with 37 CFR 41.31; or (3) a Request
a) The period for reply expires 3 months from the mailing date of the	ne final rejection.	
b) The period for reply expires on: (1) the mailing date of this Advis no event, however, will the statutory period for reply expire later Examiner Note: If box 1 is checked, check either box (a) or (b). (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).	than SIX MONTHS from the mailing DNLY CHECK BOX (b) WHEN THE	date of the final rejection. FIRST REPLY WAS FILED WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date on v have been filed is the date for purposes of determining the period of extens under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the short set forth in (b) above, if checked. Any reply received by the Office later that may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	on and the corresponding amount o ened statutory period for reply origir	of the fee. The appropriate extension fee nally set in the final Office action; or (2) as
2. The Notice of Appeal was filed on A brief in complian filing the Notice of Appeal (37 CFR 41.37(a)), or any extensio Notice of Appeal has been filed, any reply must be filed withir AMENDMENTS	n thereof (37 CFR 41.37(e)), to	avoid dismissal of the appeal. Since a
	prior to the data of filing a brief	will not be entered because
 The proposed amendment(s) filed after a final rejection, but (a) They raise new issues that would require further consider (b) They raise the issue of new matter (see NOTE below); 		
(c) They are not deemed to place the application in better to appeal; and/or	orm for appeal by materially red	lucing or simplifying the issues for
(d) ☐ They present additional claims without canceling a corr NOTE: (See 37 CFR 1.116 and 41.33(a)).	esponding number of finally reje	ected claims.
4. The amendments are not in compliance with 37 CFR 1.121.	See attached Notice of Non-Cor	mpliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):		
 Newly proposed or amended claim(s) would be allowed non-allowable claim(s). 		
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provide. The status of the claim(s) is (or will be) as follows:		be entered and an explanation of
Claim(s) allowed: Claim(s) objected to:		
Claim(s) rejected: <u>1-5,12-43 and 52-54</u> . Claim(s) withdrawn from consideration: <u>8-11 and 44-52</u> .		
AFFIDAVIT OR OTHER EVIDENCE		
 The affidavit or other evidence filed after a final action, but be because applicant failed to provide a showing of good and su was not earlier presented. See 37 CFR 1.116(e). 		
 The affidavit or other evidence filed after the date of filing a N entered because the affidavit or other evidence failed to over showing a good and sufficient reasons why it is necessary an 	come <u>all</u> rejections under appea d was not earlier presented. Se	ll and/or appellant fails to provide a ee 37 CFR 41.33(d)(1).
10. ☑ The affidavit or other evidence is entered. An explanation of REQUEST FOR RECONSIDERATION/OTHER		•
11. The request for reconsideration has been considered but do See Continuation Sheet.	, , , , , ,	
12. ☑ Note the attached Information <i>Disclosure Statement</i>(s). (PTo 13. ☐ Other:	O/SB/08) Paper No(s). <u>06/23/20</u>	006
	/Kenneth R Horlick/ Primary Examiner, Art U	nit 1637

Continuation of 11. does NOT place the application in condition for allowance because:

Applicant's reply has failed to overcome the claim rejections, as follows.

Declaration under 37 CFR 1.132 is Insufficient

The declaration under 37 CFR 1.132 filed 11/14/2008 is insufficient to overcome the rejection of claims 1-5, 12-43, and 52-54 based upon Latorra et al. (2003) and Koizumi et al. as set forth in the last Office action as follows.

The declaration presents the position that Latorra et al. in Table 1 and Figure 2 did not teach a Locked Nucleic Acid (LNA) as the third nucleotide from the 3' end of an oligonucleotide. While Examiner does not agree with this position; regardless it is evident that Latorra et al. teach that Locked Nucleic Acids can be placed in various positions of primers which are oligonucleotides, especially near the 3' end (see the 2nd sentence of the 3rd paragraph on p. 79) and specifically teach the last four nucleotides of primers from the 3' end which includes the third nucleotide. Thus it would have been obvious to one of ordinary skill in the art at the time of the claimed invention to have a LNA as the third nucleotide from the 3' end of an oligonucleotide. Koizumi et al. teach 2'-O,4'-C-ethylene nucleic acid (ENA) units and teach LNA units. Thus, as also given previously, it would have been obvious to simply substitute the ENA units of Koizumi et al. for the LNA units of Lattora et al. to arrive at the claimed invention.

Furthermore, the declaration does not provide evidence that the substituting an LNA or an ENA as third nucleotide from the 3' end results in any unexpected result.

The declaration further presents the argument that Koizumi et al do not teach a modified oligonucleotide used for a protein-DNA molecular interaction. However, the protein which Applicant cites is a polymerase and the modified oligonucleotide is a primer used to elongate/amplify DNA. However, Latoora et al. teach modified primer interactions/amplifications in Polymerase Chain Reaction (PCR, entire article).

In view of the foregoing, when all of the evidence is considered, the totality of the rebuttal evidence of nonobviousness fails to outweigh the evidence of obviousness.

Claim Rejections Maintained - 35 USC § 103

The rejection of claims 1-5, 23, 29, and 41 under 35 U.S.C. 103(a) as being unpatentable over Latorra et al. (06/04/2003) and Koizumi et al. (2003) is maintained. Applicant's arguments have been fully considered but they are not persuasive. Applicant's argument in reply are those found in the declaration which are addressed above.

The rejection of claims 12-19 and 52-54 are rejected under 35 U.S.C. 103(a) as being unpatentable over Latorra et al., Koizumi et al., and Weston et al. (2002) is maintained. Applicant's arguments have been fully considered but they are not persuasive. Applicant argues that Weston et al. do not teach the claimed modified olignucleotide. However, Latorra et al. and Koisumi et al. are relied upon for this teaching.

The rejection of claims 20-22, 24-28, 30-40, and 42-43 under 35 U.S.C. 103(a) as being unpatentable over Latorra et al. and Koizumi et al., and further in view of Stanton et al. (2001) is maintained. Applicant's arguments have been fully considered but they are not persuasive. Applicant argues that Stanton et al. do not teach the claimed modified olignucleotide. However, Latorra et al. and Koisumi et al. are relied upon for this teaching.

Thus the rejections are maintained.

Priority

Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). Receipt has been acknowledged of the certified English translations of the 2003-378039 filed in Japan and 2004-121080 application filed in Japan and submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file (see section 5 of Office Action mailed on 08/20/2008). Copies of the certified copies of the priority documents have been received.

Examiner further confirms and acknowledges the NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495 mailed on 10/06/2006.

/M. S./ Examiner, Art Unit 1637 December 4, 2008